title: Differential effect of gonadotropin-releasing hormone analogue treatment on estrogen levels and sulfatase activity in uterine leiomyoma and myometrium.
abstract: OBJECTIVE
  To investigate the effect of GnRH treatment on estrogen levels and sulfatase activity in leiomyoma and myometrium tissue.
  
  
  METHODS
  Retrospective analyses of tissue obtained in a prospective randomized clinical study.
  
  
  METHODS
  Gynecology departments of eight hospitals in the Netherlands.
  
  
  METHODS
  Thirty-two patients scheduled for leiomyoma surgery.
  
  
  METHODS
  Patients were randomized to receive either GnRHa (3.75 mg/4 weeks of triptorelin or 3.6 mg/4 weeks of goserelin) or no GnRHa for 4 months. At subsequent surgery, leiomyoma and myometrium samples were collected.
  
  
  METHODS
  Estrone, estradiol, and sulfatase activity levels in leiomyoma and myometrium.
  
  
  RESULTS
  In myometrium, levels of estrone, estradiol, and sulfatase activity were significantly lower in the treated group (to median values of 46%, 21%, and 61%, respectively). In leiomyomas of treated patients, the reduction in median estrone level (to 65% of untreated value) was comparable to that in myometrium. The reduction in estradiol level in leiomyoma, however, was significantly less than in myometrium (median to 58% vs. 21%), and no significantly lower sulfatase activity was found.
  
  
  CONCLUSIONS
  Estradiol and sulfatase results show that the effect of GnRHa treatment on leiomyoma differs from the effect on myometrium, suggesting a continuing estrogenic stimulus in leiomyoma tissue despite treatment.
authors.affiliation: University Medical Center and Faculty of Pharmacy, Utrecht University, The Netherlands.
authors.forename: Joost
authors.initials: J
authors.lastname: van de Ven
authors.forename: Truus H
authors.initials: TH
authors.lastname: Donker
authors.forename: Marinus A
authors.initials: MA
authors.lastname: Blankenstein
authors.forename: Joseph H
authors.initials: JH
authors.lastname: Thijssen
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D004958:Estradiol / Q000378:metabolism*; D005260:Female; D017273:Goserelin / Q000627:therapeutic use*; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy / Q000378:metabolism*; D009215:Myometrium / Q000378:metabolism*; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D013429:Sulfatases / Q000378:metabolism*; D017329:Triptorelin Pamoate / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000378:metabolism*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017329:Triptorelin Pamoate; D017273:Goserelin; D004958:Estradiol; D013429:Sulfatases; C020121:estrone sulfatase